Literature DB >> 8432795

Reduced postprandial cholecystokinin (CCK) secretion in patients with noninsulin-dependent diabetes mellitus: evidence for a role for CCK in regulating postprandial hyperglycemia.

R A Rushakoff1, I D Goldfine, L J Beccaria, A Mathur, R J Brand, R A Liddle.   

Abstract

The plasma cholecystokinin (CCK) response to a test meal was studied in 16 control subjects and 15 patients with noninsulin-dependent diabetes mellitus (NIDDM). Basal CCK levels were approximately 1 pmol in both groups. However, after the test meal, plasma CCK levels were 2-fold greater in the controls when compared to the diabetics. In controls, CCK levels maximally increased by 5.6 +/- 0.8 pmol (mean +/- SEM) 10 min after feeding, whereas in the NIDDM patients this value was 1.9 +/- 0.6 pmol (P < 0.001). After the test meal, the normal subjects showed no postprandial rise in blood glucose, whereas the diabetic patient showed a rise of 2.6 +/- 0.7 mmol. To determine whether the decreased CCK levels may have been related to the postprandial hyperglycemia, 7 diabetic subjects were infused with CCK. With this CCK infusion, postprandial glucose levels did not rise. These data suggest, therefore: 1) a role for cholecystokinin in regulating postprandial hyperglycemia in man, 2) abnormalities in CCK secretion occur in NIDDM and may contribute to the hyperglycemia seen in this disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8432795     DOI: 10.1210/jcem.76.2.8432795

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

Review 1.  Human pancreatic exocrine response to nutrients in health and disease.

Authors:  J Keller; P Layer
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

2.  Lipid transport in cholecystokinin knockout mice.

Authors:  Alexandra King; Qing Yang; Sarah Huesman; Therese Rider; Chunmin C Lo
Journal:  Physiol Behav       Date:  2015-07-11

Review 3.  Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.

Authors:  Robert E Steinert; Christine Feinle-Bisset; Lori Asarian; Michael Horowitz; Christoph Beglinger; Nori Geary
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

4.  Gastric neuropeptides and gastric motor abnormality in streptozotocin-induced diabetic rats: observation for four weeks after streptozotocin.

Authors:  Y Miyamoto; M Yoneda; A Morikawa; H Itoh; I Makino
Journal:  Dig Dis Sci       Date:  2001-08       Impact factor: 3.199

5.  The cholecystokinin receptor agonist, CCK-8, induces adiponectin production in rat white adipose tissue.

Authors:  Adrián Plaza; Beatriz Merino; Nuria Del Olmo; Mariano Ruiz-Gayo
Journal:  Br J Pharmacol       Date:  2019-06-20       Impact factor: 8.739

6.  Gene Networks of Hyperglycemia, Diabetic Complications, and Human Proteins Targeted by SARS-CoV-2: What Is the Molecular Basis for Comorbidity?

Authors:  Olga V Saik; Vadim V Klimontov
Journal:  Int J Mol Sci       Date:  2022-06-29       Impact factor: 6.208

7.  Fasting and meal-induced CCK and PP secretion following intragastric balloon treatment for obesity.

Authors:  Elisabeth M H Mathus-Vliegen; Gerrit H de Groot
Journal:  Obes Surg       Date:  2013-05       Impact factor: 4.129

8.  Impaired insulin secretion and enhanced insulin sensitivity in cholecystokinin-deficient mice.

Authors:  Chun-Min Lo; Silvana Obici; H Henry Dong; Michael Haas; Dawnwen Lou; Dae Hyun Kim; Min Liu; David D'Alessio; Stephen C Woods; Patrick Tso
Journal:  Diabetes       Date:  2011-05-20       Impact factor: 9.461

Review 9.  Pancreatic regulation of glucose homeostasis.

Authors:  Pia V Röder; Bingbing Wu; Yixian Liu; Weiping Han
Journal:  Exp Mol Med       Date:  2016-03-11       Impact factor: 8.718

10.  Is there an association between type 1 diabetes in children and gallbladder stones formation?

Authors:  Abdulrahman A Al-Hussaini; Ahmed S Alenizi; Musa D AlZahrani; Nimer M Sulaiman; Mannan Khan
Journal:  Saudi J Gastroenterol       Date:  2013 Mar-Apr       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.